KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Q3 2025 value amounting to $30.0 million.

  • Rigel Pharmaceuticals' Non-Current Debt fell 4985.27% to $30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.0 million, marking a year-over-year decrease of 4985.27%. This contributed to the annual value of $52.4 million for FY2024, which is 6.68% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Non-Current Debt of $30.0 million as of Q3 2025, which was down 4985.27% from $37.5 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Non-Current Debt peaked at $59.8 million during Q3 2024, and registered a low of $19.8 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Debt was $39.5 million (2022), whereas its average is $41.0 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Non-Current Debt surged by 10189.24% in 2021 and then plummeted by 4985.27% in 2025.
  • Rigel Pharmaceuticals' Non-Current Debt (Quarter) stood at $19.9 million in 2021, then skyrocketed by 98.09% to $39.4 million in 2022, then surged by 32.76% to $52.4 million in 2023, then grew by 0.07% to $52.4 million in 2024, then crashed by 42.82% to $30.0 million in 2025.
  • Its last three reported values are $30.0 million in Q3 2025, $37.5 million for Q2 2025, and $44.9 million during Q1 2025.